Restricted accessResearch articleFirst published online 2014-11
Prognostic Value of Serum Von Willebrand Factor,but Not Soluble Icam and Vcam,for Mortality and Cardiovascular Events is Independent of Residual Renal Function in Peritoneal Dialysis Patients
We explored associations between markers of endothelial dysfunction and outcome events, and whether those associations were independent of residual renal function (RRF) in patients on peritoneal dialysis.
Methods
The study enrolled 261 incident patients and 68 healthy control subjects who were followed till death, censoring, or study end. Demographics, biochemistry, markers of inflammation (C-reactive protein) and endothelial dysfunction [soluble intercellular adhesion molecule 1 (sICAM), soluble vascular adhesion molecule 1 (sVCAM), and von Willebrand factor (vWf)] were examined at baseline. Outcome events included all-cause death and fatal and nonfatal cardiovascular (CV) events.
Results
Mean levels of vWf, sICAM, and sVCAM were significantly higher in patients than in healthy control subjects. Levels of sICAM and sVCAM, but not vWf, were significantly correlated with RRF. Levels of sICAM and vWf both predicted all-cause mortality and fatal and nonfatal CV events after adjustment for recognizable CV risk factors. The association between sICAM and outcome events disappeared after further adjustment for RRF. However, RRF did not change the predictive role of vWf for outcome events. Compared with the lowest vWf quartile (6.6% – 73.9%), the highest vWf quartile (240.9% – 1161%) predicted the highest risk for fatal and nonfatal CV events (adjusted hazard ratio: 2.05; 95% confidence interval: 1.15 to 3.64; p = 0.014). We observed no associations between sVCAM and RRF, or sVCAM and any outcome event.
Conclusions
The prognostic value of vWf, but not sICAM, is independent of RRF in predicting mortality and CV events.
SarnakM.J., LeveyA.S., SchoolwerthA.C., CoreshJ., CulletonB., HammL.L.Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention.Hypertension2003; 42: 1050–65.
YilmazM.I., SonmezA., QureshiA.R., SaglamM., StenvinkelP., YamanH.Endogenous testosterone, endothelial dysfunction, and cardiovascular events in men with nondialysis chronic kidney disease.Clin J Am Soc Nephrol2011; 6: 1617–25.
4.
ZoccaliC., Bode–BogerS., MallamaciF., BenedettoF., TripepiG., MalatinoL.Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study.Lancet2001; 358: 2113–17.
5.
SulimanM.E., QureshiA.R., HeimbürgerO., LindholmB., StenvinkelP.Soluble adhesion molecules in end-stage renal disease: a predictor of outcome.Nephrol Dial Transplant2006; 21: 1603–10.
6.
WangA.Y., LamC.W., WangM., WooJ., ChanI.H., LuiS.F.Circulating soluble vascular cell adhesion molecule 1: relationships with residual renal function, cardiac hypertrophy, and outcome of peritoneal dialysis patients.Am J Kidney Dis2005; 45: 715–29.
7.
StamF., van GuldenerC., SchalkwijkC.G., ter WeeP.M., DonkerA.J., StehouwerC.D.Impaired renal function is associated with markers of endothelial dysfunction and increased inflammatory activity.Nephrol Dial Transplant2003; 18: 892–8.
8.
OchodnickyP., VettorettiS., HenningR.H., BuikemaH., Van DokkumR.P., de ZeeuwD.Endothelial dysfunction in chronic kidney disease: determinant of susceptibility to end-organ damage and therapeutic response.J Nephrol2006; 19: 246–58.
9.
WangA.Y.The John F. Maher Award Recipient Lecture 2006. The “heart” of peritoneal dialysis: residual renal function.Perit Dial Int2007; 27: 116–24.
10.
DongJ., WangT., WangH.Y.The impact of new comorbidities on nutritional status in continuous ambulatory peritoneal dialysis patients.Blood Purif2006; 24: 517–23.
11.
EngelsteinE.D.Sudden cardiac death. In: AlexanderR.W., SchlantR.C., FusterV., O'RourkeR.A., RobertsR., SonnenblickE.H., eds. Hurst's the Heart, Arteries and Veins.9th ed.New York, NY: McGraw–Hill; 1998: 1081–112.
12.
NakaiK., ItohC., KawazoeK., MiuraY., SotoyanagiH., HottaK.Concentration of soluble vascular cell adhesion molecule-1 (VCAM-1) correlated with expression of VCAM-1 mRNA in the human atherosclerotic aorta.Coron Artery Dis1995; 6: 497–502.
LentingP.J., WesteinE., TerraubeV., RibbaA.S., HuizingaE.G., MeyerD.An experimental model to study the in vivo survival of von Willebrand factor. Basic aspects and application to the R1205H mutation.J Biol Chem2004; 279: 12102–9.
18.
SchootenC.J., TjernbergP., WesteinE., TerraubeV., CastamanG., MourikJ.A.Cysteine-mutations in von Willebrand factor associated with increased clearance.J Thromb Haemost2005; 3: 2228–37.
19.
BlannA.D.Normal levels of von Willebrand factor antigen in human body fluids.Biologicals1990; 18: 351–3.
20.
PéquériauxN.C., FijnheerR., GemenE.F., BarendrechtA.D., DekkerF.W., KredietR.T.Plasma concentration of von Willebrand factor predicts mortality in patients on chronic renal replacement therapy.Nephrol Dial Transplant2012; 27: 2452–7.
21.
RumleyA., LoweG.D., SweetnamP.M., YarnellJ.W., FordR.P.Factor VIII, von Willebrand factor and the risk of major ischaemic heart disease in the Caerphilly Heart Study.Br J Haematol1999; 105: 110–16.
22.
SmithF.B., LeeA.J., FowkesF.G., PriceJ.F., RumleyA., LoweG.D.Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh Artery Study.Arterioscler Thromb Vasc Biol1997; 17: 3321–5.
23.
DaneshJ., WheelerJ.G., HirschfieldG.M., EdaS., EiriksdottirG., RumleyA.C-Reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease.N Engl J Med2004; 350: 1387–97.
24.
DeaconA.C.Clinical problem-solving: still hazy after all these years.N Engl J Med1995; 332: 332–3.
25.
WhincupP.H., DaneshJ., WalkerM., LennonL., ThomsonA., ApplebyP.Von Willebrand factor and coronary heart disease: prospective study and meta-analysis.Eur Heart J2002; 23: 1764–70.
26.
FolsomA.R., WuK.K., RosamondW.D., SharrettA.R., ChamblessL.E.Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study.Circulation1997; 96: 1102–8.
27.
SaitoI., FolsomA.R., BrancatiF.L., DuncanB.B., ChamblessL.E., McGovernP.G.Nontraditional risk factors for coronary heart disease incidence among persons with diabetes: the Atherosclerosis Risk in Communities (ARIC) Study.Ann Intern Med2000; 133: 81–91.
28.
JagerA., van HinsberghV.W., KostenseP.J., EmeisJ.J., YudkinJ.S., NijpelsG.Von Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and nondiabetic subjects: the Hoorn Study.Arterioscler Thromb Vasc Biol1999; 19: 3071–8.
29.
PapayianniA., AlexopoulosE., GiamalisP., GionanlisL., BelechriA.M., KoukoudisP.Circulating levels of ICAM-1, VCAM-1, and MCP-1 are increased in haemodialysis patients: association with inflammation, dyslipidaemia, and vascular events.Nephrol Dial Transplant2002; 17: 435–41.
30.
StenvinkelP., LindholmB., HeimbürgerM., HeimbürgerO.Elevated serum levels of soluble adhesion molecules predict death in pre-dialysis patients: association with malnutrition, inflammation, and cardiovascular disease.Nephrol Dial Transplant2000; 15: 1624–30.
31.
PapagianniA., KalovoulosM., KirmizisD., VainasA., BelechriA.M., AlexopoulosE.Carotid atherosclerosis is associated with inflammation and endothelial cell adhesion molecules in chronic haemodialysis patients.Nephrol Dial Transplant2003; 18: 113–19.
32.
ChoiH.Y., LeeJ.E., HanS.H., YooT.H., KimB.S., ParkH.C.Association of inflammation and protein-energy wasting with endothelial dysfunction in peritoneal dialysis patients.Nephrol Dial Transplant2010; 25: 1266–71.
33.
NanayakkaraP.W., van GuldenerC., ter WeeP.M., SchefferP.G., van IttersumF.J., TwiskJ.W.Effect of a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on carotid intima-media thickness, endothelial function, and renal function in patients with mild to moderate chronic kidney disease: results from the Anti-Oxidant Therapy in Chronic Renal Insufficiency (ATIC) Study.Arch Intern Med2007; 167: 1262–70.
